A clinical trial found that nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy. The results of the trials were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23. Antiangiogenic drugs are anticancer drugs designed to cut off the blood supply that brings tumors the nutrients they need ...Monday, 28 October 2013
Resistance to Certain Anticancer Drugs? New Nanopharmaceutical may Come In Handy
A clinical trial found that nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy. The results of the trials were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23. Antiangiogenic drugs are anticancer drugs designed to cut off the blood supply that brings tumors the nutrients they need ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment